$LNSR

LENSAR (NASDAQ: LNSR) updates 10-K with governance, pay and control data

LENSAR, Inc. (NASDAQ: LNSR) has filed an Amendment No. 1 to its annual report (Form 10-K/A) to include comprehensive Part III disclosures, which detail information on directors, executive compensation, ownership, related-party transactions, and auditor fees for the fiscal year ended December 31, 2025. The filing clarifies that North Run Capital and affiliates beneficially own approximately 55% of LENSAR's common stock and hold 45.1% of combined voting power, stemming from a $20.0 million investment in Series A Convertible Preferred Stock and warrants made in 2024. The amendment also outlines the 2025 compensation for key executives, with CEO Nicholas T. Curtis receiving over $2.3 million.

Original reporting
Published May 1, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 1, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LNSR
Neutral
medium confidence
Mentioned
$LNSR · $LNSR
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$LNSRNeutralLow
01

Why it matters

The disclosure clarifies major ownership stakes and executive compensation, which could influence investor perceptions and long-term stability.

02

Market read

While important for long-term stakeholders, the news has limited immediate trading impact for short-term traders.

03

What to watch

Potential future changes in ownership structure or executive compensation policies could alter the company's strategic direction.

Timing: long-term

Background

LENSAR recently filed an amendment to its annual report, providing detailed disclosures on governance, ownership, and executive pay for fiscal year ending December 31, 2025.

Company-level read

Ticker impact

$LNSRNeutralMedium confidence
Context

The news pertains directly to LENSAR's corporate governance, ownership structure, and executive compensation, which are significant factors for long-term investors and institutional stakeholders.

Expected impact

Minimal short-term price movement expected; potential for long-term stability or volatility depending on corporate governance developments.

Evidence & confidence

While the disclosure clarifies ownership and compensation, it does not indicate immediate operational changes or market-moving events.

$LNSRNeutralMedium confidence
Context

The news is highly relevant for long-term investors and institutional traders interested in corporate governance and ownership structures.

Expected impact

No significant immediate impact; potential for gradual influence on stock performance.

Evidence & confidence

The information enhances understanding of company control but lacks immediate catalysts for trading actions.

Market effects

The disclosures may reinforce governance standards within the life sciences sector, potentially influencing peer companies.

Limited regional impact; primarily relevant to U.S. markets and institutional investors.

Low; specific to company and sector-level considerations.

Counterpoint

Some investors may view increased ownership concentration as a potential risk for minority shareholders, possibly leading to governance concerns.

Key entities

  • North Run Capital

    A significant investor holding approximately 55% of LENSAR's common stock.

  • Nicholas T. Curtis

    CEO of LENSAR, received over $2.3 million in compensation for 2025.

Related articles

$LNSRHighAI 9/10

Why is LENSAR stock surging today?

Investing.com reports LENSAR (LNSR) shares rose 16.1% in pre-open after Q2 results beat expectations. The company posted EPS of $0.10 vs consensus -$0.21 and revenue of $16.5M vs $15M. It cited 18% YoY revenue growth, 20% recurring revenue growth, and first positive net income, with 10 ALLY systems placed.

$LNSRMed

LENSAR, Inc. (LNSR): Results of Operations and Financial Condition

LENSAR, Inc. (LNSR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LENSAR ® Reports Second Quarter 2026 Results and Provides Business Update 10 ALLY Robotic Cataract Laser Systems ® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Tot

$LNSRMedAI 9/10

Lensar (LNSR) Q4 2025 Earnings Transcript

Lensar reported Q4 2025 revenue of $16 million, down 4% mainly from lower system sales, including weaker sales outside the U.S. The company placed 15 ALLY systems (12 U.S., 1 outside) and grew its installed base to just over 200 ALLY systems (+48%). Recurring revenue rose 17% to $12.7 million (79% of Q4 revenue). Gross margin was 43% ($6.9 million). Management said the Alcon acquisition termination restored independence and full title to a $10 million deposit; 2026 cash operating expenses are ex

$ELMed

Estee Lauder outlook revised to stable by S&P on deleveraging

S&P Global Ratings revised Estee Lauder's outlook to stable from negative, citing improved operating results and credit metrics. The agency expects adjusted leverage to fall to 1.9x by fiscal 2027, with mid-single-digit revenue growth and expanded EBITDA margins. Cash flows are projected to decline due to restructuring and investments, but the company plans to use cash balances for debt repayment.

$AZNMedAI 8/10

AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss

AstraZeneca's breast cancer drug camizestrant (Etcamah) failed to meet the primary endpoint in the Phase III SERENA-4 trial, missing a key growth opportunity. The trial showed no statistically significant improvement in progression-free survival. AstraZeneca's shares fell 3% in after-hours trading. The drug remains approved for ESR1-mutated patients, with strong Phase III data supporting this indication. AstraZeneca's overall oncology portfolio and pipeline remain robust, with first-half 2026 re

$LHXHigh

L3Harris Is Down 30% and Guggenheim Calls It a Buy

L3Harris Technologies (LHX) gained 0.43% premarket after Guggenheim initiated coverage with a Buy rating and $365 price target, suggesting 49% upside. The stock is near its 52-week low, down 30% in six months. Guggenheim expects sustained growth and defense spending tailwinds. Jefferies started coverage at Hold with a $315 target, citing leadership changes and missile IPO uncertainty.